Cleveland Clinic Diabetes Therapeutics, Technology and Surgery 2021
YOU WILL GET THE COURSE VIA LIFETIME DOWNLOAD LINK (FAST SPEED) AFTER PAYMENT
For over twenty five years, Cleveland Clinic has been at the forefront of diabetes treatment, research and education. Its world class faculty has designed Diabetes Therapeutics, Technology and Surgery to provide up-to-date reviews of management strategies and research on the complications of this disease. It includes a detailed analysis of therapeutic options applicable to type 1 and type 2 diabetes, as well as their complications
Diabetes Day, Therapeutics, Technology and Surgery, is presented by the Cleveland Clinic Department of Endocrinology, Diabetes and Metabolism to provide up-to-date reviews of management strategies and research on the complications of diabetes. Key topic areas that will be addressed include a review of therapeutic options to manage both type 1 and 2 diabetes and the complications, including a pump update, dual hormone therapies, sulfonylureas, GLP1 agonists, metformin, and the role of exercise and fasting. New this year is a discussion of the pathophysiologic impact of COVID-19. The goal of this course is to increase practitioners’ competence and clinical performance to treat diabetes and its complications and, ultimately, to improve patient outcomes.
In addition to receiving speaker slides both pre and post course, participants will be given access to the live stream recording post course.
After participating in this live stream activity, practitioners will be able to:
- Describe the efficacy and side effects of therapeutic innovations for type 1 diabetes, including closed-loop insulin pumps, dual hormone therapy, and glucagon.
- Compare the effectiveness of new and emerging therapies for both type 1 and 2 diabetes.
- Critically appraise the impact of bariatric surgery on patients with type 2 diabetes.
- Describe options for treating children with type 2 diabetes.
- Compare the data on effectiveness of diets and exercise in diabetes strategies.
- Summarize research defining the pathophysiologic impact of nonalcoholic steatohepatitis.
- Describe how COVID-19 affects the progression of diabetes in infected patients.
Cleveland Clinic Diabetes Therapeutics, Technology and Surgery
Session 1: Type 1 Diabetes Corner
Pump Update | Diana Isaacs, PharmD, BCPS, BC-ADM, CDE |
Dual Hormone Pumps | Keren Zhou, MD |
Do It Yourself Technology | Julia Blanchette, PhD, RN, CDCES |
New Insulins | Robert S. Zimmerman, MD |
Dawn of Glucagon | Vinni Makin, MD |
Session 2: Focus on Type 2 Diabetes
Cardiovascular Outcomes of Bariatric Surgery in Patients with Obesity and Diabetes | Ali Aminian, MD |
Are Sulfonyureas Safe? | Pratibha Rao, MD |
Treatment of Type 2 Diabetes in Children | Jamie Wood, MD |
New Treatment Options for Diabetes and the Kidney | Alexandra Mikhael, MD |
GLP-1 Agonists: Oral VS. SubQ | Mario Skugor, MD |
Non-Alcoholic Fatty Liver Disease (NAFLD) Is an Early Manifestion of the Metabolic Syndrome | Adi Mehta, MD |
Treatment of Hyperlipidemia in Type 2 Diabetes: Review of Current Guidelines | Dennis Bruemmer, MD, PhD |
Session 3: Fasting, Metformin and Management Issues
Intermittent Fasting and Diabetes: What’s the Evidence? | Carolyn Garvey, RDN, LD, CDCES |
Management of Hypoglycemia Post Gastric Bypass | Sangeeta Kashyap, MD |
Role of Exercise in Management of Diabetes | Oscar Morey Vargas, MD |
Understanding Metformin’s Actions Through the Interactions in the Gut | Leann Olansky, MD |
T2D and CVD: Metformin Monotherapy | Kevin M. Pantalone, DO, ECNU, FACE |
Diabetes Management in Patients with COVID-19 | Sana Hasan, DO |
Endoscopic and Surgical Division of the Gastric Pylorus for Gastroparesis | Joshua Landreneau, MD |
Release Date: 7/1/21